Filtered By:
Condition: Asthma

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 404 results found since Jan 2013.

Cationic polyaspartamide-based nanocomplexes mediate siRNA entry and down-regulation of the pro-inflammatory mediator high mobility group box 1 in airway epithelial cells
In conclusion, we have found optimal conditions for down-regulation of HMGB1 by siRNA delivery mediated by polyaminoacidic polymers in airway epithelial cells in the absence of cytotoxicity. Functional and in-vivo studies are warranted. Graphical abstract
Source: International Journal of Pharmaceutics - July 11, 2015 Category: Drugs & Pharmacology Source Type: research

Evaluation of nasal epithelium sampling as a tool in the preclinical development of siRNA-based therapeutics for asthma.
Abstract The development of siRNA-based asthma therapeutics is currently hampered by a paucity of relevant biomarkers and the need to ascertain tissue-specific gene targeting in the context of active disease. Epithelial STAT6 expression is fundamental to asthma pathogenesis in which inflammatory changes are found throughout the respiratory tract. Therefore, to improve preclinical evaluation, we tested the efficacy of STAT6-targeting siRNA within nasal epithelial cells (NEC's) obtained from asthmatic and non-asthmatic donors. STAT6 expression was invariant in both donor groups and amenable to suppression by siRNA t...
Source: J Cell Mol Med - February 13, 2013 Category: Molecular Biology Authors: Healey GD, Evans N, Hopkin JM, Davies G, Walker W Tags: J Cell Mol Med Source Type: research

siRNA delivery to macrophages using aspherical, nanostructured microparticles as delivery system for pulmonary administration.
Abstract The delivery of oligonucleotides such as siRNA to the lung is a major challenge, as this group of drugs has difficulties to overcome biological barriers due to its polyanionic character and the associated hydrophilic properties, resulting in inefficient delivery. Especially in diseases such as asthma, chronic obstructive pulmonary disease and cystic fibrosis, where increased proinflammation is present, a targeted RNA therapy is desirable due to the high potency of these oligonucleotides. To address these problems and to ensure efficient uptake of siRNA in macrophages, a microparticulate, cylindrical deliv...
Source: European Journal of Pharmaceutics and Biopharmaceutics - December 4, 2020 Category: Drugs & Pharmacology Authors: Fischer T, Tschernig T, Drews F, Brix K, Meier C, Simon M, Kautenburger R, Schneider M Tags: Eur J Pharm Biopharm Source Type: research

Spray drying siRNA-lipid nanoparticles for dry powder pulmonary delivery
This study verifies the successful spray drying procedure of LNP-siRNA systems maintaining their integrity and mediating strong gene silencing efficiency on mRNA and protein levels both in vitro and ex vivo. The successful spray drying procedure of LNP-siRNA formulations in 5% lactose solution creates a novel siRNA-based therapy option to target respiratory diseases such as lung cancer, asthma, COPD, cystic fibrosis and viral infections.PMID:36126785 | DOI:10.1016/j.jconrel.2022.09.021
Source: Cancer Control - September 20, 2022 Category: Cancer & Oncology Authors: Christoph M Zimmermann Domizia Baldassi Karen Chan Nathan B P Adams Alina Neumann Diana Leidy Porras-Gonzalez Xin Wei Nikolaus Kneidinger Mircea Gabriel Stoleriu Gerald Burgstaller Dominik Witzigmann Paola Luciani Olivia M Merkel Source Type: research

Pulmonary Delivery of siRNA via Polymeric Vectors as Therapies of Asthma
Asthma is a chronic inflammatory disease. Despite the fact that current therapies, such as the combination of inhaled corticosteroids and β2‐agonists, can control the symptoms of asthma in most patients, there is still an urgent need for an alternative anti‐inflammatory therapy for patients who suffer from severe asthma but lack acceptable response to conventional therapies. Many molecular factors are involved in the inflammatory process in asthma, and thus blocking the function of these factors could efficiently alleviate airway inflammation. RNA interference (RNAi) is often thought to be the answer in the search for...
Source: Archiv der Pharmazie - July 1, 2015 Category: Drugs & Pharmacology Authors: Yuran Xie, Olivia M. Merkel Tags: Minireview Source Type: research

Blockade of Mbd2 by siRNA-loaded liposomes protects mice against OVA-induced allergic airway inflammation via repressing M2 macrophage production
ConclusionsThe above data indicate that Mbd2 implicates in the pathogenesis of asthma predominantly by regulating the polarization of M2 macrophages, which supports that Mbd2 could be a viable target for treatment of asthma in clinical settings.
Source: Frontiers in Immunology - August 25, 2022 Category: Allergy & Immunology Source Type: research

TAT Decorated siRNA Polyplexes For Inhalation Delivery in Anti-asthma Therapy
Eur J Pharm Sci. 2023 Sep 15:106580. doi: 10.1016/j.ejps.2023.106580. Online ahead of print.ABSTRACTIn this work, a novel protonable copolymer was designed to deliver siRNA through the inhalation route, as an innovative formulation for the management of asthma. This polycation was synthesized by derivatization of α,β-poly(N-2-hydroxyethyl)D,L-aspartamide (PHEA) first with 1,2-Bis(3-aminopropylamino)ethane (bAPAE) and then with a proper amount of maleimide terminated poly(ethylene glycol) (PEG-MLB), with the aim to increase the superficial hydrophilicity of the system, allowing the diffusion trough the mucus layer. Once t...
Source: European Journal of Pharmaceutical Sciences - September 17, 2023 Category: Drugs & Pharmacology Authors: Salvatore Emanuele Drago Marta Cabibbo Emanuela Fabiola Craparo Gennara Cavallaro Source Type: research

TAT decorated siRNA polyplexes for inhalation delivery in anti-asthma therapy
Eur J Pharm Sci. 2023 Sep 16;190:106580. doi: 10.1016/j.ejps.2023.106580. Online ahead of print.ABSTRACTIn this work, a novel protonable copolymer was designed to deliver siRNA through the inhalation route, as an innovative formulation for the management of asthma. This polycation was synthesized by derivatization of α,β-poly(N-2-hydroxyethyl)D,L-aspartamide (PHEA) first with 1,2-Bis(3-aminopropylamino)ethane (bAPAE) and then with a proper amount of maleimide terminated poly(ethylene glycol) (PEG-MLB), with the aim to increase the superficial hydrophilicity of the system, allowing the diffusion trough the mucus layer. On...
Source: European Journal of Pharmaceutical Sciences - September 17, 2023 Category: Drugs & Pharmacology Authors: Salvatore Emanuele Drago Marta Cabibbo Emanuela Fabiola Craparo Gennara Cavallaro Source Type: research

A new combination therapy for asthma using dual-function dexamethasone-conjugated polyethylenimine and vitamin D binding protein siRNA
T Rhim
Source: Gene Therapy - September 21, 2017 Category: Genetics & Stem Cells Authors: M Choi J Gu M Lee T Rhim Source Type: research

PDK1/RSK1-dependent C/EBP{beta} activation is involved in thrombin-induced expression of orosomucoid 1-like 3 (ORMDL3) and IL-8/CXCL8 in human lung epithelial cells
In this study, we investigated that the role of phosphoinositide-dependent kinase 1 (PDK1), ribosomal S6 kinase 1 (RSK1), and CCAAT/enhancer-binding protein β (C/EBPβ) in thrombin-induced expression of ORMDL3 and IL-8/CXCL8 in human lung epithelial cells (A549). We found that treatment of cells with thrombin caused ORMDL3 mRNA and protein expression. Thrombin-induced IL-8/CXCL8-luciferase activity or IL-8/CXCL8 release was inhibited by ORMDL3 siRNA, BX-912 (a PDK1 inhibitor), and PDK1 siRNA. Moreover, thrombin-stimulated ORMDL3 expression was attenuated by BX-912, PDK1 siRNA, RSK1 siRNA, and C/EBPβ siRNA. Th...
Source: European Respiratory Journal - December 6, 2017 Category: Respiratory Medicine Authors: Chen, B.-C., Huang, M.-F. Tags: Airway Pharmacology and Treatment Source Type: research

CD80 and CD86 knockdown in dendritic cells regulates Th1/Th2 cytokine production in asthmatic mice.
Authors: Li JG, DU YM, Yan ZD, Yan J, Zhuansun YX, Chen R, Zhang W, Feng SL, Ran PX Abstract Dendritic cells (DCs) are associated with the activation and differentiation of T helper (Th) cells. Cluster of differentiation (CD)80 and CD86, the co-stimulatory molecules highly expressed in DCs, have are prominent in promoting the differentiation of Th cells toward Th2 cells. However, little is known about the effect of CD80 and CD86 knockdown on Th1/Th2 cytokine production in mature DCs (mDCs). The aim of the present study was to investigate whether small-interfering RNA (siRNA) could suppress the surface expression of...
Source: Experimental and Therapeutic Medicine - March 23, 2016 Category: Journals (General) Tags: Exp Ther Med Source Type: research

Small interfering RNA against CD86 during allergen challenge blocks experimental allergic asthma
Conclusion: These results suggest that local administration of CD86 siRNA during the effector phase ameliorates lines of asthma phenotypes. Targeting airway dendritic cells with siRNA suppresses airway inflammation and hyperresponsiveness in an experimental model of allergic asthma.
Source: Respiratory Research - October 27, 2014 Category: Respiratory Medicine Authors: Yukari Asai-TajiriKoichiro MatsumotoSatoru FukuyamaKeiko Kan-oTakako NakanoKen TonaiTatsukuni OhnoMiyuki AzumaHiromasa InoueYoichi Nakanishi Source Type: research

Oligonucleotides —A Novel Promising Therapeutic Option for IBD
Conclusions In this review, we focused on recent and past approaches to test the therapeutic efficacy of oligonucleotide based therapies in IBD. The combining mechanistic mode of oligonucleotide based therapeutics is a targeted action on specific pro-inflammatory molecules, which are over activated in IBD patients and contribute significantly to disease pathogenesis. The proposed high selectivity of the agents is derived from its mode of action, that aims to specifically block certain inflammatory molecular patterns, without a general systemic effect on other molecular targets. It would be important for each oligonucleot...
Source: Frontiers in Pharmacology - April 23, 2019 Category: Drugs & Pharmacology Source Type: research

Current Drug Targeting using siRNAbased Nano Therapeutics for Pulmonary Diseases
Curr Pharm Des. 2022 Jul 27. doi: 10.2174/1381612828666220727144223. Online ahead of print.ABSTRACTThe importance of siRNA in nano drug delivery systems to target important pulmonary disorders such as chronic obstructive pulmonary disease (COPD), asthma, lung cancer, and others is reviewed in this perspective. The great majority of lung illnesses are caused by protein misfolding. As a result, siRNA-based therapies are increasingly being used to target the gene. Given the difficulties of delivering bare siRNA, siRNA protection may ensure its efficacy in gene therapy. These issues could be solved with a nano-based siRNA deli...
Source: Current Pharmaceutical Design - July 27, 2022 Category: Drugs & Pharmacology Authors: Venkateshwaran Krishnaswami Ruckmani Kandasamy Source Type: research